HCV Next - Remember Risk–Benefits of DAAs Still Weigh Heavily on the Benefits

The following articles appeared in the February print edition of HCV NEXT, provided online at Healio.

Table of Contents
5 Questions
A Conversation With Anita Howe, PhD

Cover Story

HCV Resistance: A Constellation of Considerations

Editorial
Remember Risk–Benefits of DAAs Still Weigh Heavily on the Benefits

Feature
Much Ado About (Almost) Nothing: The Impact of PPIs and DAAs

In the Journals
Increased Conflict of Interest Policies Needed for Guideline Committees, Advocacy Organizations

Black, Hispanic HCV Patients More Likely to Fail DAA Therapy

HCV Eradication Reduces Complications in Patients With Cirrhosis

Daclatasvir/Asunaprevir Safe, Effective in HCV, Renal Dysfunction

Trend Watch

Report Raises Questions About Long-Term Effects of DAAs for HCV

Officials: Patients of PA Dental Practice Should Test for HIV, Hepatitis

AbbVie Submits NDA for Pan-Genotypic HCV Regimen

New HCV Regimen Effective in Japanese Genotype-1 Patients